Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.07	$1.90	$1.43 ▼ $4.26	$207.85M	1.62	142,030 shs	122,856 shs
FDMT 4D Molecular Therapeutics	$4.22 -3.2%	$3.96	$2.24 ▼ $19.69	$195.51M	2.81	754,383 shs	316,866 shs
VTYX Ventyx Biosciences	$3.16 -3.4%	$2.16	$0.78 ▼ $3.39	$224.87M	0.93	1.43 million shs	933,414 shs
ZIVO ZIVO Bioscience	$13.25	$15.30	$5.80 ▼ $22.15	$50.58M	-0.06	953 shs	4 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	0.00%	+1.47%	+10.11%	+39.86%	-40.52%
FDMT 4D Molecular Therapeutics	0.00%	-1.40%	+2.18%	+37.01%	-70.69%
VTYX Ventyx Biosciences	0.00%	+15.33%	+39.82%	+179.65%	+23.92%
ZIVO ZIVO Bioscience	0.00%	-1.85%	-6.82%	+10.42%	+60.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	2.2123 of 5 stars	3.5	1.0	0.0	0.0	3.4	0.8	0.6
FDMT 4D Molecular Therapeutics	2.2669 of 5 stars	3.3	3.0	0.0	0.0	1.4	1.7	0.6
VTYX Ventyx Biosciences	2.9507 of 5 stars	3.4	5.0	0.0	0.0	0.6	2.5	0.6
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	479.71% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	600.37% Upside
VTYX Ventyx Biosciences	2.75	Moderate Buy	$10.00	216.46% Upside
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZIVO, VTYX, ACIU, and FDMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
5/9/2025	FDMT 4D Molecular Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $38.00
5/1/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
4/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$31.02M	6.70	N/A	N/A	$1.29 per share	1.60
FDMT 4D Molecular Therapeutics	$40K	4,887.82	N/A	N/A	$11.05 per share	0.38
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$3.59 per share	N/A
ZIVO ZIVO Bioscience	$15.85K	3,190.87	N/A	N/A	($0.81) per share	-16.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$57.83M	-$0.58	N/A	N/A	N/A	-177.79%	-44.60%	-22.25%	8/5/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/6/2025 (Estimated)
VTYX Ventyx Biosciences	-$135.12M	-$1.75	N/A	N/A	N/A	N/A	-47.45%	-43.49%	8/14/2025 (Estimated)
ZIVO ZIVO Bioscience	-$7.78M	-$4.93	N/A	∞	N/A	N/A	N/A	-2,240.92%	8/12/2025 (Estimated)

Latest ZIVO, VTYX, ACIU, and FDMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.6922	N/A	N/A	N/A	$0.52 million	N/A
8/14/2025	Q2 2025	VTYX Ventyx Biosciences	-$0.45	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ACIU AC Immune	-$0.18	N/A	N/A	N/A	$1.98 million	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
5/8/2025	Q1 2025	VTYX Ventyx Biosciences	-$0.48	-$0.39	+$0.09	-$0.39	N/A	N/A
4/30/2025	Q1 2025	ACIU AC Immune	-$0.22	-$0.21	+$0.01	-$0.21	$1.99 million	$1.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.53	1.53
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
VTYX Ventyx Biosciences	N/A	19.57	19.57
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
FDMT 4D Molecular Therapeutics	99.27%
VTYX Ventyx Biosciences	97.88%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
FDMT 4D Molecular Therapeutics	9.60%
VTYX Ventyx Biosciences	18.18%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	95.79 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
VTYX Ventyx Biosciences	30	71.16 million	58.22 million	Optionable
ZIVO ZIVO Bioscience	10	3.82 million	2.91 million	Not Optionable

ZIVO, VTYX, ACIU, and FDMT Headlines

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Passes Below 50 Day Moving Average - What's Next?

June 25, 2025 | marketbeat.com

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20, 2025 | businesswire.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.comM

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.comM

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 1, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.comM

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

October 26, 2023 | markets.businessinsider.com

Zivo Bioscience to effect reverse stock split to regain compliance with Nasdaq rules

October 26, 2023 | msn.com

Adam Zivo: Nazi veteran’s memoir lays bare the pitfalls of nationalism

October 5, 2023 | nationalpost.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO, VTYX, ACIU, and FDMT Company Descriptions

AC Immune NASDAQ:ACIU

$2.07 0.00 (0.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.13 +0.06 (+3.14%)

As of 04:30 AM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

4D Molecular Therapeutics NASDAQ:FDMT

$4.22 -0.14 (-3.21%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.46 +0.25 (+5.81%)

As of 07:52 AM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Ventyx Biosciences NASDAQ:VTYX

$3.16 -0.11 (-3.36%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.16 +0.00 (+0.16%)

As of 07:12 AM Eastern

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

ZIVO Bioscience NASDAQ:ZIVO

$13.25 0.00 (0.00%)

As of 07/18/2025

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time